Business Segments And Geographic Information

12 Months Ended

Sep. 24, 2011

Business Segments And Geographic Information [Abstract]

Business Segments And Geographic Information

13. Business Segments and Geographic Information

The Company reports segment information in accordance with ASC 280, Segment Reporting. Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions how to allocate resources and assess performance. The Company's chief operating decision maker is the chief executive officer, and the Company's reportable segments have been identified based on the types of products manufactured and the end markets to which the product are sold. Each reportable segment generates revenue from either the sale of medical equipment and related services and/or sale of disposable supplies, primarily used for diagnostic testing and surgical procedures. The Company has four reportable segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. Certain reportable segments represent an aggregation of operating units within each segment. The Company measures and evaluates its reportable segments based on segment revenues and operating income (loss) adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, contingent consideration charges, and other one-time or unusual items.

Identifiable assets for the four principal operating segments consist of inventories, intangible assets including goodwill, and property and equipment. The Company fully allocates depreciation expense to its four reportable segments. The Company presents all other identifiable assets as corporate assets. There were no intersegment revenues. Segment information for fiscal years 2011, 2010 and 2009 is as follows:

	Years ended
	September 24, 2011		September 25, 2010			September 26, 2009
Total revenues:
Breast Health	$	825,551	$	755,542		$	728,884
Diagnostics		571,263		552,501			547,892
GYN Surgical		300,538		283,142			264,900
Skeletal Health		91,997		88,367			95,458
	$	1,789,349	$	1,679,552		$	1,637,134
Operating income (loss):
Breast Health	$	187,970	$	(93,623	)	$	(122,559	)
Diagnostics		170,693		100,469			(809,640	)
GYN Surgical		3,623		53,071			(1,097,685	)
Skeletal Health		12,159		10,020			13,210
	$	374,445	$	69,937		$	(2,016,674	)
Depreciation and amortization:
Breast Health	$	40,776	$	47,992		$	50,764
Diagnostics		161,710		166,124			157,562
GYN Surgical		90,632		68,848			56,341
Skeletal Health		11,618		11,804			9,257
	$	304,736	$	294,768		$	273,924
Capital expenditures:
Breast Health	$	12,069	$	10,392		$	10,966
Diagnostics		23,128		18,317			30,823
GYN Surgical		11,467		9,575			9,689
Skeletal Health		2,198		3,637			807
Corporate		6,801		4,737			5,949
	$	55,663	$	46,658		$	58,234
Identifiable assets:
Breast Health	$	985,196	$	988,041		$	1,133,714
Diagnostics		1,770,107		1,802,148			1,942,494
GYN Surgical		2,049,682		1,834,773			1,860,834
Skeletal Health		31,864		30,293			30,937
Corporate		1,171,931		970,579			716,247
	$	6,008,780	$	5,625,834		$	5,684,226

As a result of the Company's long-lived assets impairment test and goodwill impairment test related to MammoSite, a reporting unit in Breast Health, performed as June 27, 2010, the Company recorded intangible asset impairment charges of $143.5 million to write down intangible assets to fair value and $76.7 million to reduce the reporting unit's goodwill. These charges are reflected in Breast Health's operating loss for fiscal 2010.

As a result of the Company's interim impairment analysis of goodwill as of December 27, 2008, the Company recorded a goodwill impairment charge of $2.34 billion during the three months ended March 28, 2009 comprised of $1.17 billion for GYN Surgical, $908.3 million for Diagnostics, and $265.9 million for Breast Health. These charges are reflected in each reportable segments' operating loss for fiscal 2009.

Products sold by the Company internationally are manufactured at domestic and international manufacturing locations. Transfers between the Company and its subsidiaries are generally recorded at amounts similar to the prices paid by unaffiliated foreign dealers. All intercompany profit is eliminated in consolidation.

The Company operates in the following major geographic areas as noted in the below chart. Product sales data is based upon customer location, and internationally totaled $362.3 million, $302.3 million and $291.4 million in fiscal 2011, 2010 and 2009, respectively. The Company's sales in Europe are predominantly derived from Germany, the United Kingdom and the Netherlands. The Company's sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The "All others" designation includes Canada, Latin America and the Middle East.

Product sales by geography as a percentage of total product sales are as follows:

	Years ended
	September 24, 2011			September 25, 2010			September 26, 2009
United States		76	%		79	%		80	%
Europe		13	%		12	%		12	%
Asia-Pacific		6	%		5	%		4	%
All others		5	%		4	%		4	%
		100	%		100	%		100	%

The Company's property and equipment, net are geographically located as follows:

	September 24, 2011		September 25, 2010		September 26, 2009
United States	$	165,177	$	183,383	$	206,630
Costa Rica		34,107		35,984		35,886
Europe		29,591		28,060		32,328
All other countries		9,791		4,271		3,533
	$	238,666	$	251,698	$	278,377